Use of non-peptidic NK1 receptor antagonists for the production of apoptosis in tumour cells
AssigneeNk-1 IP Limited
InventorMiguel Muñoz Sáez
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of substance P antagonists and, in particular, the use of non-peptidic NK1 receptor antagonists for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human Hodgkin's lymphoma KM-H2, lymphoblastic leukaemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human Ewing's sarcoma, human glioma and human osteosarcoma.
Claims4
A method of inducing apoptosis in melanoma cells comprising contacting the melanoma cells with a non-peptide NK1 receptor antagonist in an amount effective to induce apoptosis, wherein the non-peptide NK1 receptor antagonist is (2S,3S)3-{[3,5-Bis(trifluoromethyl)phenyllmetoxi}-2-phenylpiperidine (L-733060) or aprepitant, wherein the melanoma cells comprise a level of NK1 receptors that is 400% to 500% of the level on non-tumor cells.
A method of treating melanoma in a human subject comprising administering a therapeutically effective amount of a non-peptide NK1 receptor antagonist, wherein the non-peptide NK1 receptor antagonist is (2S,3S)3-{[3,5-Bis(trifluoromethyl)phenyllmetoxi}-2-phenylpiperidine (L-733060) or aprepitant, wherein the melanoma cells comprise a level of NK1 receptors that is 400% to 500% of the level on non-tumor cells.
Dependencies are inferred from the claim text.